Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Schmit

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
AIDS (London, England)|February 24, 2001
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapyF D Goebel, R Hemmer, J C Schmit, et al.
The Journal of Infectious Diseases|November 1, 1996
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strainJ C Schmit, J Cogniaux, P Hermans, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|October 1, 1996
Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor testA M Vandamme, J C Schmit, S Van Dooren, et al.
AIDS (London, England)|April 24, 2001
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeK Van Laethem, M Witvrouw, C Pannecouque, et al.
AIDS (London, England)|December 1, 1996
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddCL Ruiz, J Romeu, J Martínez-Picado, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2001
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through JE Fontaine, C Riva, M Peeters, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1997
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virusM Witvrouw, J Balzarini, C Pannecouque, et al.
AIDS (London, England)|April 19, 2000
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavirK Van Laethem, M Witvrouw, J Balzarini, et al.
AIDS (London, England)|November 14, 1998
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countriesJ C Schmit, K Van Laethem, L Ruiz, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityM Witvrouw, M E Arranz, C Pannecouque, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
AIDS (London, England)|February 24, 2001
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapyF D Goebel, R Hemmer, J C Schmit, et al.
The Journal of Infectious Diseases|November 1, 1996
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strainJ C Schmit, J Cogniaux, P Hermans, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|October 1, 1996
Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor testA M Vandamme, J C Schmit, S Van Dooren, et al.
AIDS (London, England)|April 24, 2001
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeK Van Laethem, M Witvrouw, C Pannecouque, et al.
AIDS (London, England)|December 1, 1996
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddCL Ruiz, J Romeu, J Martínez-Picado, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2001
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through JE Fontaine, C Riva, M Peeters, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1997
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virusM Witvrouw, J Balzarini, C Pannecouque, et al.
AIDS (London, England)|April 19, 2000
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavirK Van Laethem, M Witvrouw, J Balzarini, et al.
AIDS (London, England)|November 14, 1998
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countriesJ C Schmit, K Van Laethem, L Ruiz, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityM Witvrouw, M E Arranz, C Pannecouque, et al.
Pageof 9